Premium
Intermittent intravenous methotrexate in the treatment of advanced epidermoid carcinoma of the cervix and vulvovagina
Author(s) -
Haffner William H. J.,
Frickii Henry Clay
Publication year - 1970
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197010)26:4<812::aid-cncr2820260412>3.0.co;2-5
Subject(s) - medicine , methotrexate , radiation therapy , cervix , epidermoid carcinoma , surgery , complication , chemotherapy , carcinoma , cancer
Epidermoid carcinoma of the cervix and vulvovagina recurring after surgery or radiotherapy has been treated with methotrexate by several routes. Regional pelvic perfusion with methotrexate has its advocates, but most now feel that the possible benefits are outweighed by the risk of complication the current study evaluates the effects of intermittent intravenous methotrexate at 0.6 mg/kg twice weekly, continuing until toxicity develops. Among the 10 patients treated, there was only one objective response, and there were 2 subjective responses. Four patients became considerably worse by the treatment. Consequently, this form of therapy has been abandoned, and there still is no effective means of treating the patient in whom surgery and radiation therapy have failed or in whom the disease is too widespread for local methods of treatment.